News and Trends 3 May 2023
Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline
Eli Lilly and Company has announced positive results of the TRAILBLAZER-ALZ 2 phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's…